Nanoscope Therapeutics Inc.
Sulagna Bhattacharya, the Chief Executive Officer and Co-Founder of Nanoscope Therapeutics Inc., also serves as a Member of the Board of Directors at the Biotechnology Innovation Organization. With experience as the CEO of Nanoscope Technologies and Co-Founder of Nanoscope Instruments, Sulagna brings a wealth of knowledge in the biotechnology industry. As an Entrepreneurs in Residence at UT Southwestern Medical Center, Sulagna continues to make significant contributions to the healthcare sector. Sulagna holds an MBA from Northwestern University - Kellogg School of Management and is actively involved in various governing boards within the industry.
Nanoscope Therapeutics Inc.
1 followers
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells. Update: June, 2021: Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa